Vertex Pharmaceuticals Inc

Quantli Newsdesk

· 5 days ago

Sionna Therapeutics discontinued development of SION-719 as an add-on to Vertex's Trikafta after the drug failed to significantly lower sweat chloride levels in a Phase 2 trial. The failure removes a near-term competitive threat to Vertex's dominant $13 billion cystic fibrosis franchise, reinforcing the company's market position.

10-K

Quantli Newsdesk

· 4 months ago

Vertex delivered $12.0 billion in total revenues for 2025, up 9% year-over-year, driven by continued CF franchise strength and meaningful contributions from newly launched ALYFTREK, CASGEVY, and JOURNAVX. Operating profitability returned to normalized levels after a 2024 Alpine acquisition charge.